PF-07038124 in Treating Atopic Dermatitis and Plaque Psoriasis

In a recent phase 2a clinical trial, published in JAMA Dermatology, PF-07038124, a topical phosphodiesterase 4 inhibitor, has shown significant promise in treating both atopic dermatitis (AD) and plaque psoriasis, 2 common inflammatory skin conditions known for their challenging management.

Conducted from December 2020 to August 2021 across 34 sites in 4 countries, the study enrolled 104 patients aged 18-70 years with mild to moderate AD or plaque psoriasis. Patients were randomly assigned to receive either PF-07038124 0.01% topical ointment or a vehicle control once daily for 6 weeks.

Patients treated with PF-07038124 demonstrated a substantial improvement in the eczema area and severity index (EASI) score, with a mean percent change from baseline of -74.9%, compared to -35.5% in the vehicle group (difference, -39.4% [90% CI, -58.8% to -20.1%]; P < .001). Similarly, patients with plaque psoriasis treated with PF-07038124 saw significant improvements in the psoriasis area and severity index (PASI) score, with a mean percent change from baseline of -4.8, compared to 0.1 in the vehicle group (difference, -4.9 [90% CI, -7.0 to -2.8]; P < .001).

Furthermore, PF-07038124 was well tolerated, with comparable rates of treatment-emergent adverse events between the treatment and vehicle groups in both AD and plaque psoriasis cohorts. Importantly, no application site reactions were reported with PF-07038124 treatment.

“Topical PF-07038124 was well tolerated and demonstrated superior efficacy compared with vehicle in patients with mild to moderate AD and plaque psoriasis,” concluded the study authors.

Reference:

Eichenfield LF, Tarabar S, Forman S, García-Bello A, Feng G, Fetterly G, Mahling P, Peeva E, Vincent MS, Chandra DE. Efficacy and safety of PF-07038124 in patients with atopic dermatitis and plaque psoriasis: a randomized clinical trial. JAMA Dermatol. 2024 Feb 1;160(2):156-163. doi: 10.1001/jamadermatol.2023.4990. PMID: 38117526; PMCID: PMC10733847.